HUTCHMED (NASDAQ:HCM) & Celldex Therapeutics (NASDAQ:CLDX) Critical Contrast

Celldex Therapeutics (NASDAQ:CLDX) and HUTCHMED (NASDAQ:HCM) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

Profitability

This table compares Celldex Therapeutics and HUTCHMED’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	-3,446.88%	-33.22%	-31.26%
HUTCHMED	N/A	N/A	N/A

Insider and Institutional Ownership

8.8% of HUTCHMED shares are held by institutional investors. 4.4% of Celldex Therapeutics shares are held by insiders. Comparatively, 3.6% of HUTCHMED shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings for Celldex Therapeutics and HUTCHMED, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	2	1	6	1	2.60
HUTCHMED	1	3	1	1	2.33

Celldex Therapeutics currently has a consensus price target of $41.56, indicating a potential upside of 34.83%. HUTCHMED has a consensus price target of $20.88, indicating a potential upside of 37.70%. Given HUTCHMED’s higher possible upside, analysts clearly believe HUTCHMED is more favorable than Celldex Therapeutics.

Valuation and Earnings

This table compares Celldex Therapeutics and HUTCHMED”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$2.60 million	787.98	-$157.86 million	($3.38)	-9.12
HUTCHMED	$630.20 million	4.20	$37.73 million	N/A	N/A

HUTCHMED has higher revenue and earnings than Celldex Therapeutics.

Risk & Volatility

Celldex Therapeutics has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 0.42, suggesting that its share price is 58% less volatile than the S&P 500.

Summary

HUTCHMED beats Celldex Therapeutics on 7 of the 12 factors compared between the two stocks.

About Celldex Therapeutics

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company’s clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

About HUTCHMED

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.